High Tech Pharm Co. Ltd (106190) - Total Liabilities
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has total liabilities worth ₩12.57 Billion KRW (≈ $8.52 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore High Tech Pharm Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.
High Tech Pharm Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See High Tech Pharm Co. Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
High Tech Pharm Co. Ltd Competitors by Total Liabilities
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ringmetall SE
XETRA:HP3A
|
Germany | €92.83 Million |
|
Baikowski SASU
PA:ALBKK
|
France | €27.90 Million |
|
Great Elm Capital Corp
NASDAQ:GECC
|
USA | $175.29 Million |
|
Suny Cellular Communication Ltd
TA:SNCM
|
Israel | ILA208.69 Million |
|
Empire State Realty OP LP ES
NYSE:ESBA
|
USA | $2.58 Billion |
|
ZOOZ Power Ltd. Ordinary Shares
NASDAQ:ZOOZ
|
USA | $6.70 Million |
|
NexMetals Mining Corp. Common Shares
NASDAQ:NEXM
|
USA | $15.56 Million |
|
Kudelski
SW:KUD
|
Switzerland | CHF228.06 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down High Tech Pharm Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 106190 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how High Tech Pharm Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual total liabilities of High Tech Pharm Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩20.35 Billion ≈ $13.79 Million |
-27.48% |
| 2023-12-31 | ₩28.06 Billion ≈ $19.02 Million |
-13.02% |
| 2022-12-31 | ₩32.26 Billion ≈ $21.86 Million |
+11.05% |
| 2021-12-31 | ₩29.05 Billion ≈ $19.69 Million |
-12.76% |
| 2020-12-31 | ₩33.30 Billion ≈ $22.57 Million |
+0.49% |
| 2019-12-31 | ₩33.14 Billion ≈ $22.46 Million |
+11.77% |
| 2018-12-31 | ₩29.65 Billion ≈ $20.09 Million |
+75.41% |
| 2017-12-31 | ₩16.90 Billion ≈ $11.46 Million |
-1.33% |
| 2016-12-31 | ₩17.13 Billion ≈ $11.61 Million |
+20.44% |
| 2015-12-31 | ₩14.23 Billion ≈ $9.64 Million |
-2.10% |
| 2014-12-31 | ₩14.53 Billion ≈ $9.85 Million |
-- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.